Skip to content

Effectiveness of Homoeopathic Medicines Azadirachta indica-Q and Echinacea angustifolia-Q in Allergy

Single Blind Randomized Comparative Study in the Modulation of Serum Immunoglobulin-E levels of Atopic patients treated with Azadirachta indica-Q and Echinacea angustifolia-Q

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021405
Enrollment
20
Registered
2019-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L500- Allergic urticaria Health Condition 2: Z910- Allergy status, other than to drugs and biological substances Health Condition 3: J45- Asthma Health Condition 4: L20- Atopic dermatitis Health Condition 5: B65-B83- Helminthiases Health Condition 6: D824- Hyperimmunoglobulin E [IgE] syndrome Health Condition 7: T784- Other and unspecified allergy Health Condition 8: R768- Other specified abnormal immunological findings in serum Health Condition 9: J30- Vasomotor and allergic

Interventions

Intervention1: Azadirachta indica-Q: 20 Drops in 10 ml of water per oral route morning and night every day half an hour before food for 90 days Control Intervention1: Echinacea angustifolia-Q: 20 Drop

Sponsors

Central Council for Research in Homoeopathy
Lead Sponsor
Vinayaka Missions Homoeopathic Medical College and Hospital
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with elevated Serum Immunoglobulin-E (IgE) level with or without any Clinical Manifestation. 2. Elevated IgE level > 158 IU/mL or as per the reference range in other Units / for other laboratory methods. 3. Patients associated with Atopic Symptoms.

Exclusion criteria

Exclusion criteria: 1. Patients with Systemic Complications 2. Patients with Autoimmune diseases. 3. Those who are already under chronic medication for elevated IgE levels.

Design outcomes

Primary

MeasureTime frame
Reduction in Serum Ig-E LevelsTimepoint: 90 Days

Secondary

MeasureTime frame
Symptomatic ReliefTimepoint: 90 days

Countries

India

Contacts

Public ContactDr H Venkatesan

Vinayaka Missions Homoeopathic Medical College and Hospital

venkathompath@gmail.com9865134561

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026